Presently, the company holds over 220 issued patents and pending patent applications world-wide, which cover novel agonists and antagonists of TLRs 7, 8 and 9.
Steven Ritter, vice president of intellectual property and contracts of Idera, said: “The claims of these issued patents provide additional coverage for our expanding portfolio of synthetic DNA-based Toll-like Receptor (TLR)-targeted compounds. Our TLR-targeted compounds, agonists and antagonists, are designed using our chemistry-based approach.”